Answers are grounded in this paper and cite their sources.
The development of genetic and serological markers of autoimmune Type I diabetes has allowed us to begin to identify subjects at risk for the development of Type I diabetes. Assessment of these variables can assign risk to subjects and permit the implementation of immune intervention trials in an attempt to alter the course of pre-diabetes. This review discusses relevant aspects of the genetics and diagnosis of pre-diabetes, and both current and future clinical trials that are attempting to prevent the full expression of clinical diabetes in these individuals.
No takes yet. Share an insight, caveat, or question.
Gottlieb et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: